

26. Synthesis of Thiazole and Fused Thiazolo Derivatives¹⁾

by Uroš Urleb*

Department of Pharmacy, University of Ljubljana, Aškerčeva 9, SLO-61000 Ljubljana, Slovenia

and Richard Neidlein and Walter Kramer

Pharmazeutisch-Chemisches Institut der Universität Heidelberg, Im Neuenheimer Feld 364, D-6900 Heidelberg

Herrn Kollegen Emanuel Vogel, Köln, zum 65. Geburtstag gewidmet

(17.VIII.92)

The syntheses of thiazole and fused thiazolo derivatives **2-4**, **6-8**, **10a-11b**, **13-16** from heterocyclic isothiocyanates **1**, **5**, **9**, and **12** bearing an ortho ester group and bifunctional reagents, such as substituted propargylamines, is described. Different regioselectivity of intramolecular nucleophilic attack of the thiourea S-atom on the C≡C bond, resulting in the formation of both thiazolo and thiazino derivatives, as well as NMR structure elucidation are discussed.

Introduction. – A variety of methods are available for the synthesis of thiazole derivatives [1], but there are only few syntheses leading to fused tricyclic thiazolo heterocycles [2]. Some fused thiazolo heterocycles possess biological or pharmacological activities [3] [4].

The syntheses of thiazole derivatives using a reaction between thiourea and a compound containing a primary halogen group adjacent to a C≡C bond has been already described [5]. High regioselectivity for this ring closure has been described with the formation of only a five-membered ring.

The cyclization reactions of thiourea derivatives prepared by the reaction of the secondary α,α -disubstituted propargylamines with isothiocyanates led to the formation of only tetrahydrothiazole derivatives [6]. This method has been also used for the syntheses of thiazolo-quinazole derivatives from methyl 2-(isothiocyanato)benzoate, and no formation of thiazino ring was observed [7]. Heterocyclic isothiocyanates bearing ester groups in *ortho*-positions are useful synthons for the syntheses of fused *N*-heterocycles by addition of substituted amines and related compounds [3] [8–11].


In the present paper, we describe the syntheses of isomeric thiazolo[3,2-*a*]pyridopyrimidine, thiazolo[2,3-*b*]- and thiazino[2,3-*b*]pteridine, and thiazolo[3,2-*a*]thieno[3,2-*d*]pyrimidine derivatives.

Results and Discussion. – The reaction between heterocyclic isothiocyanates and substituted propargylamines proceeds in three steps. The first step is the formation of a thiourea derivative, which could not be isolated. The second step is an intramolecular nucleophilic attack of the thiourea S-atom onto the C≡C bond.

¹⁾ Partly presented at ESOC 7, Namur, Belgium, 1991.


Regioselectivity in a ring closure by internal nucleophilic attack has been described [5] [12]. For nucleophilic attack of the S-atom at the $C\equiv C$ bond, the bonding distances are close enough for both five- and six-membered ring formation [13], and according to *Baldwin's* ring closure rules, both are favored [12]. We observed different regioselectivity of nucleophilic attack of the S-atom at the $C\equiv C$ bond, and the formation of both thiazolo[2,3-*b*]- and thiazino[2,3-*b*]pteridine derivatives (*cf.* *Scheme 4*). In other reactions, thiazino derivatives were formed in a small amount, according to $^1\text{H-NMR}$ spectra. In some cases, we could not separate both products. The third step is further condensation of thiazolo and/or thiazino derivatives to fused systems.

Ethyl 3-isothiocyanatopyridine-2-carboxylate (**1**) [9] reacted with 1,1-dimethyl-2-propynylamine to 2,3-dihydro-3,3-dimethyl-2-methylidene-5-oxopyrido[3,2-*a*]thiazolo[3,2-*a*]pyrimidine (**2**) and with eth-1-ynylcyclohexylamine to compounds **3** and **4** (*Scheme 1*). Both reactions formed five-membered rings, which could be isolated and detected




with NMR spectroscopy. Two *doublets* with a 2J values of *ca.* 2.5 Hz are characteristic for an exocyclic methylidene group. In the NMR spectrum of the evaporated reaction mixture, we observed also signals for the thiazino isomer which was not isolated (*ca.* 5%).


An analogous treatment of ethyl 2-isothiocyanato-3-pyridinecarboxylate (**5**) [9] with 1,1-dimethylpropargylamine gave 2,3-dihydro-3,3-dimethyl-2-methylidene-5-oxopyrido[2,3-*d*]thiazolo[3,2-*a*]pyrimidine (**6**; *Scheme 2*) and in a very little amount the thiazino derivative (*ca.* 5%) which was observed in the $^1\text{H-NMR}$ spectrum of the crude reaction product and was not isolated and purified. For the thiazino ring, two *doublets* of low



intensity with a 3J value of *ca.* 10 Hz at 5.65 and 6.09 ppm were observed. In the reaction of eth-1-ynylcyclohexylamine with isothiocyanato-ester **5**, the expected fused product was not formed. In this case, we isolated only the thiazolo derivative **7** and the thiazino derivative **8** in ratio 1.78:1 (Scheme 3).




Methyl 3-isothiocyanatopyrazine-2-carboxylate (**9**) [10] reacted with substituted propargylamines with low regioselectivity in the second reaction step (Scheme 4) leading to a mixture of both five- and six-membered fused rings, *i.e.* thiazolo[2,3-*b*]pteridine derivatives **10a** and **10b** and thiazino[2,3-*b*]pteridine derivatives **11a** and **11b** which could not be separated chromatographically. The ratio of the products **10a/11a** is according to $^1\text{H-NMR}$ *ca.* 1:1.2, and for **10b/11b** the ratio is 3.6:1.




For the thiazino compounds, we observed two *dublets* with a 3J value of *ca.* 10.6 Hz which is characteristic for olefinic protons (see *Exper. Part*).

When methyl 3-isothiocyanatothiophene-2-carboxylate (**12**) [3] was heated with 1,1-dimethylpropargylamine in MeOH, it underwent a transformation to give 6,7-dihydro-7,7-dimethyl-6-methylidene-9-oxothiazolo[3,2-*a*]thieno[3,2-*d*]pyrimidine (**13**), which is a less known ring system [4]. In benzene, the reaction product was methyl 3-[(4,5-dihydro-4,4-dimethyl-5-methylidene-thiazol-2-yl)amino]thiophene-2-carboxylate (**14**; *Scheme 5*).

Scheme 5

Isothiocyanate **12** reacted with eth-1-ynylcyclohexylamine at elevated temperature, and prolonged reaction in MeOH or benzene led to methyl 3-[(4-methylidene-3-thia-1-azaspiro[4.5]dec-1-en-2-yl)amino]thiophene-2-carboxylate (**15a**). Further reaction of **15a** with *t*-BuOK led to 6',7'-dihydro-6'-methylidenespiro[cyclohexane-1,7'-thiazolo[3,2-*a*]thieno[3,2-*d*]pyrimidin-9'-one (**16**; *Scheme 6*).

Scheme 6

The prototropic tautomerism in heterocyclic compounds involves the shift of a proton between a ring N-atom and a substituent atom connected to the ring. The relative position of a functional group with respect to the hetero atoms often determines the tautomeric nature of such compounds [14]. Dihydrothiazoles, bearing protomeric amino group in a position corresponding to enamine function, are in tautomeric equilibrium with this functional group [2]. In the case of the dihydrothiazoles **3**, **7**, **14**, and **15**, a proton shift between two N-atoms forming an amidine-like substructure with an endocyclic or exocyclic C=N bond has to be discussed.

Previously, we used the selective heteronuclear $^{13}\text{C}\{^1\text{H}\}$ -NOE technique for the analysis of the tautomerism in the pteridine system [10], and now we have applied this NMR technique for the determination of the tautomerism of compound **15** in a solution.

The assignment of the ^{13}C -NMR spectrum of **15** was achieved by comparison of the ^{13}C -chemical shifts of methyl 3-aminothiophene-2-carboxylate (**17**) [15]. Furthermore, an unambiguous assignment of the tertiary and quaternary C-atoms of **15** and **17** was supported by analysis of the coupling patterns in the gated-decoupled ^{13}C -NMR spectra (see *Exper. Part* for coupling constants, *cf.* [21]), selective heteronuclear $^{13}\text{C}\{^1\text{H}\}$ decoupling and NOE experiments, and finally by a long-range heteronuclear shift-correlation experiment (HC-COSY) of **15** (Fig. 1).

To decide whether the exchangeable proton of compound **15** is bonded to the exocyclic N-atom (tautomer **15a**) or to the ring N-atom of the dihydrothiazole ring (tautomer **15b**), we irradiated at the resonance frequency of NH (9.26 ppm) in the ^1H -NMR




Fig. 1. $2\text{D-}^1\text{H}, ^{13}\text{C}$ -NMR Spectrum of **15a** (250.13/62.89 MHz, long-range shift correlation)




Fig. 2. 62.89-MHz ^{13}C -NMR Spectrum of **15a** (CDCl_3). a) Proton-noise decoupled, b) NOE-difference spectrum after irradiation of H-N.

spectrum of the compound **15**, which resulted in signal enhancements of C(2'), C(3'), C(2), and COOCH_3 (Fig. 2).

An energy-optimized molecular model (ALCHEMY II) [16] of **15a** (Fig. 3) demonstrates that the range of distances between H-N and these C-atoms is significantly smaller than in the tautomeric form **15b** (**15a**: 1.946 Å (C(2)) to 2.644 Å (COOCH_3); **15b**:




Fig. 3. Molecular model of **15a** and **15b** (drawing without H-atoms (= open valences) except of N-H for better overview)

1.986 Å (C(2)) to 4.359 Å (C(7))). Because of the relative short distance between H–N and C(4) in isomer **15b** (in our molecular model *ca.* 2.11 Å), the lack of a signal enhancement of C(4) may be interpreted as an argument against structure **15b**, which clearly has to be discarded.

The conclusion, that the observed NOEs do not arise from tautomer **15b** but from the tautomer **15a** is also supported by the fact that heteronuclear NOE's in ¹³C-NMR spectra are difficult to determine for distances ≥ 2.9 Å because of the critical signal/noise ratio in such cases [17]. The small signals in the ¹³C-NMR spectrum of **15a** (Fig. 2) are due to impurities and do not arise from tautomer **15b**. As we have found only one set of signals in the ¹³C-NMR spectra of **4**, **7**, and **14** too, tautomeric equilibria seem not to be existent for the presented dihydrothiazoles with the tautomer containing an exocyclic C=N bond in a detectable concentration by NMR spectroscopy.

U. U. thanks the *Alexander von Humboldt Foundation* for the award of a research fellowship. We gratefully acknowledge a partial financial support from the Ministry for Science and Technology of the Republic of Slovenia and for generous support of this work by *Verband der Chemischen Industrie, Fonds der Chemie, BASF AG, Bayer AG, and Hoechst AG*. We are indebted to Mrs. *A. Schormann* for her help in measuring NMR spectra, to Mr. *H. Rudy* for measuring mass spectra, and Mrs. *M. Kastelic*, Mr. *G. Beutel*, and Mr. *P. Weyrich* for carrying out microanalyses and IR spectra.

Experimental Part

General. M.p.: *Reichert* hot-stage microscope, uncorrected. IR Spectra (in KBr, cm⁻¹): *Perkin-Elmer 325* and *Perkin-Elmer FTIR 1600* instruments. NMR Spectra in CDCl₃: ¹H- and ¹³C-NMR: *Bruker WM-250* spectrometer, 5 mm ¹H/¹³C dual probehead (¹H; 250.13 MHz, ¹³C; 62.89 MHz) and *Varian VXR 300* spectrometer (¹H; 300 MHz); δ in ppm rel. to TMS; multiplicities and coupling constants in ¹³C-NMR from gated-decoupled spectra (size 32 K; sweep width 7812.5 Hz (Hz/Pt = 0.477) and 7462.7 Hz (Hz/Pt = 0.455) for **17** and **15a**, resp. ¹H,¹³C-COSY Spectrum: sequence: D1-90°(¹H)-D0-180°(¹³C)-D0-D3-90°(¹H), 90°(¹³C)-D4-BB,FID; 90° ¹H pulse 12 μ s, 180° ¹³C pulse 14 μ s, relaxation delay D1 = 3s, polarization time D3 = refocussing time D4 = 64.94 ms (optimized for $J = 7.7$ Hz), 90° spectral width 7462.7 Hz in F2, 1054.9 Hz in F1, data matrix 4096 \times 512 (zero-filling in F1), 56 scans during 256 time increments, 2 dummy scans, *Lorentz* to *Gauss* multiplication in F1 (LB = -3, GB = 0.3), exponential multiplication in F2 (LB = 1). Selective heteronuclear ¹³C{¹H}-NOE Difference Spectrum (*cf.* [18] [19]). 80 mg/0.5 ml CDCl₃. Size: 16 K, sweep width 11111 Hz, decoupling power for selective CW pre-irradiation 51 dB below 0.2 W, decoupling powder for broad band decoupling 0 dB below 0.2 W, decoupling time 3 s, switch delay for appropriate settings of decoupler frequency, power and decoupler status twice 0.05 s, recycling time 3.837 s, pulse length 4 μ s (*ca.* 50° pulse), 8200 acquisitions each and off-resonance (200 scans, 8 dummy scans, 41 cycles), exponential multiplication of the difference FID prior to *Fourier* transformation (LB = 1). EI-MS: *Varian MAT 311* mass spectrometer. Elemental analyses: *Heraeus C,H,N,O* rapid analyzer and *Perkin-Elmer 2400 CHN* analyzer.

2,3-Dihydro-3,3-dimethyl-2-methylidenepyrido[3,2-d]thiazolo[3,2-a]pyrimidin-5-one (2). To a soln. of *ethyl 3-isothiocyanatopyridine-2-carboxylate (1)* [**8**] (0.28 g, 1.3 mmol) in MeOH (7 ml), 1,1-dimethylprop-2-ynylamine (0.14 g, 1.3 mmol) was added, and the mixture was heated at reflux for 6 h, precipitated product was filtered off and purified using column chromatography (silica gel, Et₂O/MeOH 3:1): 0.08 g (23%) of **3**. M.p. 129–131°. IR: 2980, 2960, 1690, 1575, 1550, 1430. ¹H-NMR: 1.98 (s, 2CH₃); 5.31, 5.42 (2d, $J = 2.7$, CH₂=); 7.62 (dd, $J(8,9) = 8.3$, H–C(8)); 7.86 (dd, H–C(9)); 8.76 (dd, $J(7,8) = 4.0$, $J(7,9) = 1.6$, H–C(7)); ¹³C-NMR: 158.7 (C(5)); 158.1 (C(10a)); 148.7 (C(7)); 145.1 (C(9a)); 144.6 (C(2)); 137.1 (C(5a)); 133.9 (C(9)); 128.5 (C(8)); 105.6 (CH₂=); 73.3 (C(3)); 26.53 (2 CH₃). MS: 245 (100, M⁺). Anal. calc. for C₁₂H₁₁N₃OS (245.31): C 58.76, H 4.52, N 17.13; found: C 59.08, H 4.25, N 16.72.

Reaction of 1 [8] and Eth-1-ynylcyclohexylamine. A soln. of **1** (0.5 g, 2.4 mmol) and eth-1-ynylcyclohexylamine (0.311 g, 2.53 mmol) in MeOH (7 ml) was heated under reflux for 8 h, evaporated under reduced pressure and separated by column chromatography (silica gel, CH₂Cl₂/acetone, 100:1 and 30:1, as solvents). The first

fraction gave, after evaporation, *ethyl 3-[(4-methylidene-3-thia-1-azaspiro[4.5]dec-1-en-2-yl)amino]pyridine-2-carboxylate* (**3**; 0.064 g, 8.1%). M.p. 106–110°. IR: 3241, 2927, 2854, 1684, 1639, 1587, 1516, 1456, 1389, 1313, 1255, 1206, 1154, 1091, 1033, 992, 856. ¹H-NMR: 1.2–1.87 (*m*, cyclohexylidene); 1.4 (*t*, *J* = 7.2, CH₃); 4.43 (*q*, *J* = 7.2, CH₂O); 5.09, 5.12 (*2d*, *J* = 1.9, CH₂=); 7.41 (*dd*, *J*(5,6) = 4.6, H–C(5)); 8.26 (*dd*, H–C(6)); 9.22 (*dd*, *J*(4,5) = 8.7, *J*(4,6) = 1.2, H–C(4)); 10.24 (*br. s*, NH). ¹³C-NMR: 167.8 (COOEt); 156.1 (C(6)); 147.7 (C(2)); 141.5 (C(4)); 116.1 (C(5)); 101.9 (CH₂=); 62.2 (CH₂O); 39.6 (C(6,10)); 25.9 (C(8)); 23.7 (C(7,9)); 14.2 (CH₃). MS: 331 (100, *M*⁺). Anal. calc. for C₁₇H₂₁N₃O₂S (331.42): C 61.60, H 6.39, N 12.68; found: C 61.28, H 6.19, N 12.60.

The second fraction gave, after evaporation, *2',3'-dihydro-2'-methylidenespiro[cyclohexane-1,3'-pyridino[3,2-a]thiazolo[3,2-d]pyrimidin]-5'-one* (**4**; 0.134 g, 25.5%). M.p. 144–146° (from EtOH). IR: 3360, 2998, 1695, 1573, 1550, 1462, 1423, 1361, 1319, 1298, 1220, 1205, 1127, 1010, 885, 820, 810, 695. ¹H-NMR: 1.5–2.02 (*m*, 8H, cyclohexylidene); 3.08–3.29 (*m*, 2H, cyclohexylidene); 5.32, 5.78 (*2d*, *J* = 2.6, CH₂=); 7.59 (*dd*, *J*(8',9') = 8.3, H–C(8')); 7.83 (*dd*, H–C(9')); 8.74 (*dd*, *J*(7',8') = 4.3, *J*(7',9') = 1.6, H–C(7')). ¹³C-NMR: 159.0 (*d*, *J* = 1.3, C(5')); 158.7 (*s*, C(10'a)); 148.6 (*ddd*, *J* = 182.3, 7.9, 3.3, C(7')); 144.5 (*dt*, *J* = 8.4, 1.7, C(9'a)); 144.0 (*m*, C(2')); 137.6 (*ddd*, *J* = 11.7, 4.6, 1.3, C(5'a)); 133.8 (*dd*, *J* = 166.8, 6.3, C(9')); 128.5 (*dd*, *J* = 165.6, 9.6, C(8')); 108.8 (*dd*, *J* = 163.5, 161.4, CH₂=); 76.1 (*br. s*, C(3')); 30.3 (C(1), C(6)); 23.3 (C(4)); 21.7 (C(3), C(5)). MS: calc. for C₁₅H₁₅N₃OS: 285.0936; found: 285.0935.

Under the same reaction conditions in benzene only compound **3** was formed in 62.8% yield.

2,3-Dihydro-3,3-dimethyl-2-methylidene-5-pyridol[2,3-d]thiazolo[3,2-a]pyrimidin-5-one (**6**). Prepared in the same manner as compound **2** in MeOH: 44.2% (from EtOH). M.p. 143–145°. IR: 3420, 3000, 1689, 1575, 1509, 1430, 1329, 1286, 1240, 1179, 1140, 1011, 895, 794. ¹H-NMR: 1.95 (*s*, 2CH₃); 5.31, 5.41 (*2d*, *J* = 1.8, CH₂=); 7.35 (*dd*, *J*(7,8) = 4.8, H–C(7)); 8.53 (*dd*, *J*(6,7) = 7.8, *J*(6,8) = 2.1, H–C(6)); 8.88 (*dd*, H–C(8)). ¹³C-NMR: 161.3 (C(5)); 160.4 (C(10a)); 157.9 (C(9a)); 156.1 (C(8)); 144.0 (C(2)); 136.3 (C(6)); 121.3 (C(7)); 115.3 (C(5a)); 105.6 (CH₂=); 73.2 (C(3)); 26.7 (2CH₃). MS: 245 (100, *M*⁺). Anal. calc. for C₁₂H₁₁N₃OS (245.31): C 58.76, H 4.52, N 17.13; found: C 58.78, H 4.62, N 17.09.

Reaction of Ethyl 2-Isothiocyanatopyridine-3-carboxylate (**5**) [11] and *Eth-1-nyllycyclohexylamine*. A soln. of **5** (0.3 g, 1.44 mmol) and eth-1-nyllycyclohexylamine (0.201 g, 1.63 mmol) in benzene or EtOH (15 ml) was heated under reflux for 4 h, evaporated under reduced pressure and separated by column chromatography (silica gel, CHCl₃/Acetone 50:1 and 30:1, as solvents). The first fraction gave, after evaporation, *ethyl 2-[(4-methylidene-3-thia-1-azaspiro[4.5]dec-1-en-2-yl)amino]pyridine-3-carboxylate* (**7**; 0.253 g, 52.8%). M.p. 145–146° (from EtOH). IR: 3210, 2940, 2930, 2860, 1698, 1628, 1605, 1582, 1510, 1460, 1450, 1395, 1370, 1310, 1290, 1260, 1145, 1090, 1072, 1025, 990, 842, 779. ¹H-NMR: 1.2–1.92 (*m*, cyclohexylidene); 1.38 (*t*, *J* = 7.1, CH₃); 4.37 (*q*, *J* = 7.1, CH₂O); 5.02, 5.16 (*2d*, *J* = 1.3, CH₂=); 6.84 (*dd*, *J*(5,6) = 4.8, H–C(5)); 8.21 (*dd*, *J*(4,5) = 7.8, *J*(4,6) = 1.6, H–C(4)); 8.34 (*dd*, *J*(5,6) = 4.8, H–C(6)); 10.7 (*br. s*, NH). ¹³C-NMR: 166.6 (*m*, COOEt); 157.1 (*ddd*, *J* = 179.5, 7.6, 3.6, C(6)); 148.7 (overlap in gated dec. spectrum, C(2)); 140.2 (*ddd*, *J* = 165.2, 6.7, 1.8, C(4)); 115.6 (*dd*, *J* = 167.9, 7.6, C(5)); 108.1 (*m*, C(3)); 100.8 (*t*, *J* = 160.5, CH₂=); 75.8 (*br. s*, C(4')); 61.7 (CH₂O); 39.7 (C(6'), C(10')); 26.0 (C(8')); 23.1 (C(7'), C(9')). MS: 331 (100, *M*⁺). Anal. calc. for C₁₇H₂₁N₃O₂S (331.42): C 61.60, H 6.39, N 12.68; found: C 61.77, H 6.53, N 12.77.

The second fraction gave, after evaporation, *ethyl 2-[(3-thia-1-azaspiro[5.5]undeca-1,4-dien-2-yl)amino]pyridine-3-carboxylate* (**8**; 29.8%). M.p. 86–87°. IR: 3302, 2930, 2855, 1693, 1618, 1589, 1499, 1451, 1421, 1368, 1328, 1288, 1256, 1182, 1136, 1086, 991, 923, 906, 814. ¹H-NMR: 1.4 (*t*, *J* = 7.1, CH₃); 1.3–1.9 (*m*, cyclohexylidene); 4.38 (*q*, *J* = 7.1, CH₂O); 5.85, 6.19 (*2d*, *J* = 9.6, H–C(4'), H–C(5')); 6.84 (*dd*, *J*(5,6) = 4.8, H–C(5)); 8.19 (*dd*, *J*(4,5) = 7.6, *J*(4,6) = 1.7, H–C(4)); 8.34 (*dd*, H–C(6)); 10.28 (*br. s*, NH). MS: 331 (73, *M*⁺), 28.8 (100, [*M* – 43]⁺). Anal. calc. for C₁₇H₂₁N₃O₂S (331.42): C 61.60, H 6.39, N 12.68; found: C 61.47, H 6.23, N 12.46.

Reaction of Methyl 3-Isothiocyanatopyrazine-2-carboxylate (**9**) [10] and *1,1-Dimethylprop-2-nylamine*. A soln. of **9** (0.42 g, 2.2 mmol) and 1,1-dimethylprop-2-nylamine (0.26 g, 2.4 mmol) in MeOH (5 ml) was heated under reflux for 6 h. Precipitated product was filtered off and recrystallized from EtOH to give 0.33 g (62%) of *2,3-dihydro-8,8-dimethyl-7-methylidene-thiazolo[2,3-b]pteridin-10-one* (**10a**) and *9,9-dimethylthiazino[2,3-b]pteridin-11-one* (**11a**) in a ratio (according to NMR data) of 1:1.2. It was not possible to separate both products. M.p. 233–235°. IR: 3440, 2990, 1708, 1575, 1519, 1450, 1410, 1320, 1283, 1235, 1210, 1160, 1130, 1110, 910, 880, 825, 725. MS: 246 (100, *M*⁺). Anal. calc. for C₁₁H₁₀N₄OS (246.29): C 53.64, H 4.09, N 22.75; found: C 53.52, H 4.04, N 22.60.

10a: ¹H-NMR: 1.99 (*s*, 2CH₃); 5.34, 5.45 (*2d*, *J* = 2.9, CH₂=); 8.66, 8.86 (*2d*, *J* = 2.1, H–C(2), H–C(3)).

11a: ¹H-NMR: 1.94 (*s*, 2CH₃); 5.70, 6.09 (*2d*, *J* = 10.7, H–C(8), H–C(7)); 8.69, 8.86 (*2d*, *J* = 2.1, H–C(2), H–C(3)).

Reaction of 9 [10] and *Eth-1-nyllycyclohexylamine*. A soln. of **9** (0.45 g, 2.3 mmol) and eth-1-nyllycyclohexylamine (0.28 g, 2.3 mmol) in EtOH (5 ml) was heated under reflux for 6 h. Precipitated product was filtered off and

recrystallized from *i*-PrOH to give 0.13 g (32%) of 2',3'-dihydro-7'-methylidenespiro[cyclohexane-1,8'-thiazolo[2,3-b]pteridin]-10'-one (**10b**) and spiro[cyclohexane-1,9'-thiazino[2,3-b]pteridin]-11'-one (**11b**) in a ratio of 3.6:1 (NMR). It was not possible to separate the products. M.p. 217–220°. IR: 3440, 2939, 2870, 1700, 1582, 1550, 1540, 1460, 1405, 1325, 1269, 1249, 1210, 1190, 1115, 1040, 900, 830, 790, 725. ¹H-NMR: 1.47–2.08 (*m*, 8 H, cyclohexylidene); 3.0–3.22 (*m*, 2 H, cyclohexylidene); 5.36, 5.80 and 6.24, 6.42 (2 × 2*d*, first set of signals *J* = 2.8, CH₂=, second set of signals *J* = 10.6, H–C(7'), H–C(8'), **11b**); 8.69, 8.84 (2*d*, *J* = 1.2, pyrazine). MS: 286 (100, *M*⁺). Anal. calc. for C₁₄H₁₄N₄OS (286.36): C 58.72, H 4.93, N 19.57; found: C 58.95, H 4.99, N 19.68.

2,3-Dihydro-7,7-dimethyl-6-methylidenethiazolo[3,2-*a*]thieno[3,2-*d*]pyrimidine (**13**). From methyl 3-isothiothiophenatothiophene-2-carboxylate (**12**; 0.32 g, 1.61 mmol) and 1,1-dimethylprop-2-nylamino (0.15 g, 1.61 mmol) in MeOH (8 ml) at reflux for 6 h. Precipitated product was filtered off and crystallized from EtOH: 0.24 g (60.6%) of **13**. M.p. 134–135°. IR: 3450, 3130, 2980, 1680, 1550, 1500, 1305. ¹H-NMR: 1.97 (*s*, 2CH₃); 5.28, 5.39 (2*d*, *J* = 1.7, CH₂=); 7.16 (*d*, *J* = 5.1, H–C(3)); 7.71 (*d*, *J* = 5.1, H–C(2)). MS: 250 (100, *M*⁺). Anal. calc. for C₁₁H₁₀N₂O₂S₂ (250.34): C 52.78, H 4.03, N 11.19; found: C 52.65, H 4.03, N 11.12.

Methyl 3-[(4,5-Dihydro-4,4-dimethyl-5-methylidenethiazol-2-yl)amino]thiophene-2-carboxylate (**14**). A soln. of **12** (0.46 g, 2.3 mmol) and 1,1-dimethylprop-2-nylamino (0.23 g, 2.8 mmol) in benzene (10 ml) was heated under reflux for 6 h, evaporated under reduced pressure, and purified by column chromatography (silica gel, CHCl₃/acetone 50:1): 0.42 g (64.5%) of **14**. M.p. 99–100°. IR: 3310, 2967, 2854, 1675, 1632, 1572, 1452, 1425, 1260, 1165, 1105, 1023, 971, 875, 780. ¹H-NMR: 1.46 (*s*, 2CH₃); 3.87 (*s*, CH₂O); 5.14, 5.16 (2*d*, *J* = 1.8, CH₂=); 7.41 (*d*, *J* = 5.5, H–C(4)); 8.11 (*d*, *J* = 5.5, H–C(5)); 9.2 (br., NH). ¹³C-NMR: 165.0 (COOMe); 156.6 (C(5')); 148.3 (C(3)); 147.2 (C(2')); 131.3 (C(5)); 122.6 (C(4)); 106.9 (C(2)); 102.4 (CH₂=); 80.0 (C(4')); 51.7 (CH₃); 30.2 (2CH₃). MS: calc. for C₁₂H₁₄N₂O₂S₂: 282.0497; found: 282.0496.

Methyl 3-[(4-Methylidene-3-thia-1-azaspiro[4.5]dec-1-en-2-yl)amino]thiophene-2-carboxylate (**15a**). A soln. of **12** (0.51 g, 2.6 mmol) and eth-1-nylcyclohexylamine (0.32 g, 2.6 mmol) in EtOH or benzene (10 ml) was heated under reflux for 6 h. Precipitated product was filtered off and recrystallized from EtOH: 0.63 g (84.8%) of **15a**. M.p. 139–142°. IR: 3320, 2949, 2859, 1685, 1670, 1640, 1612, 1572, 1451, 1420, 1408, 1281, 1255, 1160, 1105, 999, 872, 780, 730. ¹H-NMR: 1.30–1.98 (*m*, cyclohexylidene); 3.88 (*s*, CH₃); 5.12, 5.19 (2*d*, *J* = 1.8, CH₂=); 7.42 (*d*, *J* = 5.6, H–C(4)); 8.20 (*d*, *J* = 5.6, H–C(5)); 9.28 (br., NH). ¹³C-NMR: 165.0 (*m*, COOMe); 157.1 (br. *s*, C(4')); 147.3 (*dd*, *J* = 11.4, 2.3, C(3)); 147.0 (*s*, C(2')); 131.3 (*dd*, *J* = 185.8, 7.3, C(5)); 122.6 (*dd*, *J* = 177.6, 4.6, C(4)); 106.8 (*dd*, *J* = 7.7, 5.5, C(2)); 101.9 (*dd*, *J* = 162.2, 159.9, CH₂=); 83.1 (br. *s*, C(5')); 51.7 (CH₃); 39.7 (C(6'), C(10')); 26.0 (C(8')); 23.8 (C(7'), C(9')). MS: 322 (100, *M*⁺). Anal. calc. for C₁₅H₁₄N₂O₂S₂ (322.45): C 55.87, H 5.63, N 8.69; found: C 55.78, H 5.61, N 8.63.

6',7'-Dihydro-6-methylidenespiro[cyclohexane-1,7'-thiazolo[3,2-*a*]thieno[3,2-*d*]pyrimidin]-9'-one (**16**). To a soln. of **15** (0.64 g, 2 mmol) in abs. toluene (10 ml), *t*-BuOK (0.09 g, 0.7 mmol) was added, the mixture stirred at reflux temp. for 6 h, and then washed with 10 ml of H₂O. The org. phase was dried (Na₂SO₄). After drying, the solvent was removed under reduced pressure and the product recrystallized from EtOH: 0.35 g (60.1%) of **16**. M.p. 98–100°. IR: 3085, 2929, 1658, 1544, 1500, 1452, 1270, 1222, 1125, 1015, 876, 782. ¹H-NMR: 1.42–2.0 (*m*, 8 H, cyclohexylidene); 3.05–3.25 (*m*, 2 H, cyclohexylidene); 5.29, 5.74 (2*d*, *J* = 1.8, CH₂=); 7.15 (*d*, *J* = 5.3, H–C(3')); 7.71 (*d*, *J* = 5.3, H–C(2')). MS: 290 (100, *M*⁺). Anal. calc. for C₁₄H₁₄N₂O₂S₂ (290.41): C 57.90, H 4.86, N 9.65; found: C 58.16, H 4.95, N 9.69.

Methyl 3-Aminothiophene-2-carboxylate (**17**). Commercial product available from Aldrich was used without further purification. ¹H-NMR: 3.81 (*s*, CH₃); 5.53 (br. *s*, NH₂); 6.51 (*d*, *J* = 5.4, H–C(4)); 7.24 (*d*, *J* = 5.4, H–C(5)). ¹³C-NMR: 164.8 (*m*, COOMe); 154.0 (*dd*, *J* = 10.5, 3.8, C(3)); 131.4 (*dd*, *J* = 184.5, 5.7, C(5)); 119.7 (*dt*, *J* = 5.3, 4.3, C(4)); 100.9 (*m*, C(2)); 51.5 (*q*, *J* = 146.9, CH₃).

REFERENCES

- [1] J. V. Metzger, in 'Comprehensive Heterocyclic Chemistry', Eds. A. R. Katritzky and C. W. Rees, Pergamon Press, Oxford, 1984, Vol. 6, pp. 235–331.
- [2] F. Sauter, W. Deinhammer, *Monatsh. Chem.* **1974**, *105*, 270, 452.
- [3] F. Kienzle, to *F. Hoffmann-La Roche AG*, EP 0043054, 1982.
- [4] F. Hiroshi, S. Toshiaki, S. Mitsuo, T. Keiichi, *JP* 63,225,383, 1988.
- [5] Y. Yura, *Chem. Pharm. Bull.* **1962**, *10*, 372.
- [6] N. R. Easton, D. R. Cassady, R. D. Dillard, *J. Org. Chem.* **1964**, *29*, 1851.
- [7] P. Thieme, H. Koenig, *Synthesis* **1973**, 426.

- [8] U. Urleb, B. Stanovnik, M. Tišler, *J. Heterocycl. Chem.* **1990**, 27, 407.
- [9] U. Urleb, B. Stanovnik, M. Tišler, *J. Heterocycl. Chem.* **1990**, 27, 413.
- [10] U. Urleb, R. Neidlein, W. Kramer, *J. Heterocycl. Chem.* **1990**, 27, 433.
- [11] U. Urleb, B. Stanovnik, M. Tišler, *J. Heterocycl. Chem.* **1990**, 27, 643.
- [12] J. E. Baldwin, *J. Chem. Soc., Chem. Commun.* **1976**, 734.
- [13] J. I. Dickstein, S. I. Miller, in 'The Chemistry of the carbon-carbon triple bond, Ed. S. Patai, John Wiley and Sons, New York, 1978, Part 2, p. 827.
- [14] A. R. Katritzky, J. M. Lagowski, in 'Advances in Heterocyclic Chemistry', Ed. A. R. Katritzky, Academic Press, New York, 1963, Vol. 1, p. 339.
- [15] M. Brnix, J. De Mendoza, R. M. Claramont, J. Elguero, *Magn. Reson. Chem.* **1985**, 23, 367.
- [16] Tripos Associates, Inc., St. Louis, Missouri, USA.
- [17] H. R. Loosli, H. Kessler, H. Oschkinat, H. P. Weber, T. J. Petcher, A. Widmer, *Helv. Chim. Acta* **1985**, 68, 682.
- [18] R. Neidlein, W. Kramer, V. Ullrich, *Helv. Chim. Acta* **1986**, 69, 898.
- [19] C. Cativiela, F. Sanchez-Ferrando, *Magn. Reson. Chem.* **1985**, 23, 1072.